Navigation Links
Trillium secures additional financing on the strength of lead program and proprietary position around the CD200 immunoregulatory pathway
Date:9/18/2008

TORONTO, Sept. 18 /PRNewswire/ - Trillium Therapeutics Inc., a privately-held biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders, announced today that it has secured $12 million in new financing from its existing investors, VenGrowth Private Equity Partners, BDC Capital and Canadian Medical Discoveries Fund (CMDF).

"We are fortunate to have the continued support of some of Canada's premier venture capital investors, especially under these trying market conditions," commented Trillium CEO Dr. Niclas Stiernholm. "These funds will allow us to advance several programs into clinical development, elevating the company to a new level and opening up new strategic possibilities in 2009."

Trillium will use the majority of the proceeds to fund clinical trials of its lead product candidate, TTI-1612, a recombinant growth factor under parallel development for the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. TTI-1612 is on track to begin clinical testing by the end of 2008, and two additional trials are projected to commence in 2009. The company's two preclinical programs, a CD200-specific monoclonal antibody for the treatment of cancer, and a CD200Fc fusion protein for the treatment of autoimmune and inflammatory diseases, continue to hold promise and to generate strong scientific and commercial interest.

"Our continued support for Trillium is driven by the quality of the lead program TTI-1612, the strong patent position around the exciting new immunoregulatory target CD200, and management's proven ability to execute partnerships," added Dr. Luc Marengere, of VenGrowth Private Equity Partners, Trillium's largest investor.

About Trillium: Trillium Therapeutics Inc. is a private biopharmaceutical company specializing in innovative therapies of immune-mediated conditions, such as autoimmune and inflammatory disorders, as well as cancer. The company's lead program, a recombinant growth factor, is being developed for the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. Trillium has two preclinical programs targeting the CD200 immunoregulatory axis; a CD200-specific monoclonal antibody for the treatment of cancer and a CD200Fc fusion protein for the treatment of autoimmune and inflammatory diseases. The company has a broad network of external academic and industry R&D collaborations, including several license agreements with major US biotechnology companies.


'/>"/>
SOURCE Trillium Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Althea Technologies Secures $12 M Credit Line to Continue Facility Growth and Expansion
2. Progenitor Cell Therapy Secures Industry Accreditation
3. BIOCOM Institute Secures Non-Profit Designation and Funding
4. Cara Therapeutics Secures $12.3 Million in Series C Extension Financing
5. OMTEC 2008 Boasts Record Attendance and Secures Premier Position as Must-attend for Orthopaedic Companies
6. Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs
7. Novasys Medical Secures $49.5 Million in Series D Financing to Expand Commercialization of Its Renessa(R) Treatment for Incontinence in Women
8. Veran Medical Technologies Secures $4.75M in First Institutional Funding
9. Northwest Secures US$4.0 Million in Debt Financing
10. D-Pharm Secures Funding From Israels Chief Scientists Office
11. Aerovance Secures $20 Million in Debt Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... Board of Directors. Todorow is the Executive Vice President for Corporate Services and ... Todorow oversees Finance, Accounts Payable, Payroll, Billing Operations, Treasury, Managed Care Contracting, Supply ...
(Date:2/8/2016)... ... 08, 2016 , ... Bulk food product inspection systems are ... stages of the production process. Despite frequently inspecting loose product prior to packaging, ... such as sacks of dry powders. , Mettler-Toledo Product Inspection's brand-new white paper ...
(Date:2/8/2016)... the development of future natural products for crop protection. In ... center in Israel and invests substantial ... has a variety of products adapted to regional needs, ... than 35 counties worldwide. ... Gold ® is used to control a broad spectrum ...
(Date:2/6/2016)... , ... February 06, 2016 , ... The Center for ... for middle and high school teachers on Wednesday February 10, 2016. This Bite ... the Smithsonian-Mason School of Conservation, located at 1500 Remount Road in Front Royal, VA ...
Breaking Biology Technology:
(Date:1/28/2016)... (NASDAQ: SYNA ), a leading developer of human interface solutions, ... 2015. --> --> Net ... compared to the comparable quarter last year to $470.5 million. Net ... or $0.93 per diluted share. --> ... fiscal 2016 grew 9 percent over the prior year period to ...
(Date:1/22/2016)... 2016 http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ... the  "Global Behavioral Biometric Market 2016-2020" ... http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ... Market 2016-2020"  report to their offering. ... http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the addition ...
(Date:1/20/2016)... Minn. , Jan. 20, 2016   MedNet ... supports the entire spectrum of clinical research, is pleased ... 2015. MedNet,s significant achievements are the result of the ... iMedNet eClinical , it,s comprehensive, easy-to-use ... --> --> Key MedNet growth achievements ...
Breaking Biology News(10 mins):